Success Metrics

Clinical Success Rate
77.8%

Based on 7 completed trials

Completion Rate
78%(7/9)
Active Trials
0(0%)
Results Posted
86%(6 trials)
Terminated
2(15%)

Phase Distribution

Ph phase_4
4
31%
Ph phase_1
1
8%
Ph not_applicable
1
8%
Ph phase_2
3
23%
Ph phase_3
4
31%

Phase Distribution

1

Early Stage

3

Mid Stage

8

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
1(7.7%)
Phase 2Efficacy & side effects
3(23.1%)
Phase 3Large-scale testing
4(30.8%)
Phase 4Post-market surveillance
4(30.8%)
N/ANon-phased studies
1(7.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

58.3%

7 of 12 finished

Non-Completion Rate

41.7%

5 ended early

Currently Active

0

trials recruiting

Total Trials

13

all time

Status Distribution
Completed(7)
Terminated(5)
Other(1)

Detailed Status

Completed7
Withdrawn3
Terminated2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
0
Success Rate
77.8%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (7.7%)
Phase 23 (23.1%)
Phase 34 (30.8%)
Phase 44 (30.8%)
N/A1 (7.7%)

Trials by Status

completed754%
unknown18%
terminated215%
withdrawn323%

Recent Activity

0 active trials
Showing 5 of 13
terminatedphase_4

Use of Conivaptan (Vaprisol) for Hyponatremic Neuro-ICU Patients

NCT00727090
completedphase_1

Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage- A Safety and Tolerability Study

NCT03000283
withdrawnphase_2

Study of Stroke Related Edema Treatments

NCT01954290
completedphase_4

Effects on Exercise Hemodynamics of Vasopressin Blockade by Conivaptan Infusion in Heart Failure Patients

NCT01752543
withdrawnphase_3

Safety and Efficacy of Conivaptan for the Correction of Hyponatremia in Neurological Patients

NCT00684164
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT00727090Phase 4

Use of Conivaptan (Vaprisol) for Hyponatremic Neuro-ICU Patients

Terminated
NCT03000283Phase 1

Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage- A Safety and Tolerability Study

Completed
NCT01954290Phase 2

Study of Stroke Related Edema Treatments

Withdrawn
NCT01752543Phase 4

Effects on Exercise Hemodynamics of Vasopressin Blockade by Conivaptan Infusion in Heart Failure Patients

Completed
NCT00684164Phase 3

Safety and Efficacy of Conivaptan for the Correction of Hyponatremia in Neurological Patients

Withdrawn
NCT00843986Phase 3

Safety and Efficacy of Conivaptan in Hyponatremic Patients With Symptomatic Acute Decompensated Heart Failure (ADHF)

Terminated
NCT00478192Phase 3

Study of Efficacy & Safety for 3 Infusion Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia

Completed
NCT00435591Phase 4

A Study of Multiple Dosing Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia

Completed
NCT00592475Phase 2

A Study to Assess the Safety and Effects of Intravenous (IV) Conivaptan on the Hepatic Hemodynamic Response in Cirrhotic Patients

Completed
NCT00379847Phase 3

An Open-Label Study of YM087 (Conivaptan) in Patients With Euvolemic or Hypervolemic Hyponatremia

Completed
NCT00057356Phase 2

Safety and Efficacy Study of YM087 (Conivaptan) in Patients With Acute Decompensated Heart Failure

Completed
NCT00806910Phase 4

Diuretic and Renal Effects of Vaprisol When Administered Along With Furosemide and Nesiritide Continuous Infusion

Withdrawn
NCT00924014Not Applicable

Comparing the Effects of Conivaptan and Diuretics on Plasma Neurohormones and Renal Blood Flow in Patients With Chronic Congestive Heart Failure

Unknown

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13